Drugs
Researchers in the United States and Italy have reported significant advances in cancer treatment, focusing on novel approaches to targeting cancer cells and angiogenesis. Study findings provide new insights into the potential of combining therapies to achieve better treatment outcomes while minimizing side effects. By investigating the role of G
Drugs
Recent studies from the United States and Japan have made significant progress in the field of adenoviral gene therapy, showing promise in the treatment of various types of cancers. Researchers have been working to improve the efficacy and safety of adenoviral vectors, which have shown limited clinical efficacy in cancer
Drugs
Combined estrogen and testosterone therapy significantly increases the risk of invasive breast cancer in women, according to a study published in the Archives of Internal Medicine. Researchers at Harvard University analyzed data from the Nurses' Health Study, a prospective cohort study involving postmenopausal women. Over a 24-year period, 4,
Drugs
Researchers in the Netherlands, Japan, and the United Kingdom have made significant advancements in the treatment of small cell lung cancer (SCLC). Their studies have explored the efficacy of third-line chemotherapy, weekly chemotherapy with paclitaxel and carboplatin, and the impact of platinum-based treatment on survival rates in elderly patients. These
Drugs
Recent studies from the United States, Canada, and Japan have made significant strides in cancer research, focusing on adenovirus-based gene therapy and its applications in treating various types of cancer. Researchers have explored the use of chimeric oncolytic adenoviruses to enhance gene transfer and oncolysis of head and neck cancer
Drugs
Researchers from the University States, Japan, and Cuba have made significant contributions to the field of cancer treatment in recent years. While there have been advances in various areas, there are still many challenges that need to be addressed in the development of effective cancer therapies. A key finding from
Cancer treatment
Research from the United States and Japan has led to significant advances in cancer treatment. Scientists have discovered new ways to improve vaccine-induced CD8+ T-cell responses and tumor immunity, suppress tumor growth, and target specific molecular pathways to inhibit tumor progression. These findings hold promise for the development of more
Cancer treatment
Researchers in the United States have made significant strides in cancer treatment research, with recent studies documenting the enhancement of Ad5-tumor necrosis factor (TNF) family member TNF-related apoptosis-inducing ligand (TRAIL) cytotoxicity against renal cell carcinoma (RCC) with histone deacetylase inhibitors. Additionally, studies have explored tumor vascular targeting therapy with viral
Drugs
Recent research in the fields of immunology and oncology has led to the development of new cancer therapies in Australia, Taiwan, and Italy. In a study published in the Journal of Immunology, researchers from the Peter MacCallum Cancer Center in Melbourne, Australia, demonstrated that the combination of anti-DR5 antibody therapy
Drugs
Roche, a leading global healthcare company, received a negative opinion from the European Committee for Medicinal Products for Human Use regarding the approval of Tarceva (erlotinib) in combination with gemcitabine chemotherapy as first-line, once-daily, oral therapy for locally advanced, inoperable or metastatic pancreatic cancer. This decision is a setback for
Cancer treatment
Researchers from Japan, the People's Republic of China, and Canada have made significant contributions to the field of cancer research with the development of gene therapy for various types of cancers. A study from Japan has reported on the evaluation of a squamous cell carcinoma adenoviral p53 gene
Cancer treatment
Researchers in the United States and Germany have published groundbreaking studies in the Journal of Immunotherapy and Clinical Cancer Research, shedding light on innovative cancer treatment modalities. The studies focus on immune suppression in the tumor microenvironment and the use of allogeneic tumor cells expressing fusogenic membrane glycoproteins (FMG) as
